Mirtazapine improves sleep and lowers anxiety and depression in cancer patients: superiority over imipramine

Cankurtaran, Eylem Şahin; Özalp, Elvan; Soygür, Haldun; Akbıyık, Derya İren; Turhan, Levent; Alkis, N

doi:10.1007/s00520-008-0425-1

Cited by 86 publications

(60 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Among cancer patients, antidepressants are used not only to treat depression, but they also treat hot flashes, sleep disturbances, pain, and multidrug resistance [11][12][13].…”

Section: Antidepressant Usementioning

confidence: 99%

Antidepressant use and risk of central nervous system metastasis

et al. 2016

View full text Add to dashboard Cite

“…Among cancer patients, antidepressants are used not only to treat depression, but they also treat hot flashes, sleep disturbances, pain, and multidrug resistance [11][12][13].…”

Section: Antidepressant Usementioning

confidence: 99%

Antidepressant use and risk of central nervous system metastasis

et al. 2016

View full text Add to dashboard Cite

“…Effects of initial, middle, and late insomnia also improved statistically in the mirtazapine group. Study visits occurred every 2 weeks, with the most impressive results seen at the first and second visits (10). Further small studies showed benefits of mirtazapine at both the 15-mg and 30-mg daily doses against the mild symptoms of depression, loss of appetite, and decline in cognition function.…”

Section: Mirtazapinementioning

confidence: 99%

Cancer-Related Depression and Potential Pharmacologic Therapies

Ginsburg

2008

Baylor University Medical Center Proceedings

View full text Add to dashboard Cite

“…Alcuni studi hanno valutato l'efficacia di mirtazapina (Tabella I) in pazienti affetti da patologia neoplastica maligna che presentavano sintomi depressivi, nausea, vomito, perdita dell'appetito, insonnia e numerosi sintomi algici [20][21][22].…”

Section: Disclosureunclassified

Usefulness of mirtazapine in cancer patients

Pasquini

Berardelli

Craba

2010

CMI

View full text Add to dashboard Cite

Troppo spesso la presenza dei disturbi depressivi in pazienti oncologici, specialmente negli anziani, è sottostimata [10] e, anche quando vengono riconosciuti, solo una parte dei pazienti riceve un trattamento adeguato, sia che si tratti di una psicoterapia di sostegno oppure un farmaco antidepressivo.Attualmente sono presenti 11 studi randomizzati-controllati [11] che confrontano l' efficacia della terapia con antidepressivi vs placebo in pazienti oncologici che presentano sintomi depressivi e d'ansia. Una delle possibili spiegazioni a tale carenza di studi controllati è la mancata aderenza di questo sottogruppo di pazienti e dei loro familiari ai trial che utilizzano placebo. A sua volta la scarsità di trial pubblicati potrebbe essere una delle cause dell'inadeguato e mancato trattamento farmacologico dei disturbi depressivi nei pazienti oncologici. La scelta della molecola antidepressiva da somministrare non INTRODUZIONELa prevalenza dei disturbi depressivi in pazienti affetti da patologie neoplastiche varia tra il 40% e il 60% [1][2][3][4]. L'esperienza della malattia neoplastica è associata a elevati livelli di distress psicologico in grado di provocare o aggravare alcuni sintomi frequentemente descritti da questi pazienti. Tra questi si annoverano l'insonnia, la cui prevalenza varia dal 30% al 50% [5], la perdita di appetito, la nausea, il vomito e l'astenia [6], con prevalenza fino all'80% in alcune patologie oncologiche [7] e numerosi sintomi algici [8,9]. Identificare l'eziologia di tali sintomi non sempre risulta agevole: questi possono derivare dalla patologia neoplastica primaria, possono rappresentare sintomi di disturbi dell'umore e d'ansia oppure possono essere secondari all' eventuale trattamento chemioterapico o radioterapico in atto. Corresponding author Gestione clinica AbstractThe rate of depression in the general population is estimated as high as 15% and is at least two to three times more common in patients with cancer. Due to the complexity and constraints of cancer care, depression is often under-recognised and under-treated. Antidepressants are the most commonly used medications, however among cancer patients there are few randomised trials comparing antidepressants to placebo. Mirtazapine is an effective antidepressant with unique and special mechanism of action characterised by high response and remission rates, relatively early onset of action and favourable side-effect profile. Several studies reported that mirtazapine has a receptor-binding profile that may be suitable for use in controlling appetite loss and nausea of cancer patients. We conducted a review of the literature on the use of mirtazapine in cancer patients. We evaluated the effectiveness of mirtazapine for the management of depressive and anxiety symptoms and for several distressing symptoms such as pain, nausea, appetite loss, and sleep disturbances.

show abstract

Mirtazapine improves sleep and lowers anxiety and depression in cancer patients: superiority over imipramine

Abstract: Our findings suggest that mirtazapine is effective for resolving insomnia as well as anxiety and depressive symptoms in cancer patients. However, more systematic research, such as placebo-controlled studies, is needed.

Cited by 86 publications

References 31 publications

Antidepressant use and risk of central nervous system metastasis

Antidepressant use and risk of central nervous system metastasis

Cancer-Related Depression and Potential Pharmacologic Therapies

Usefulness of mirtazapine in cancer patients

Contact Info

Product

Resources

About